Schild H J, Kyewski B, Von Hoegen P, Schirrmacher V
Institute for Immunology and Genetics, German Cancer Research Center, Heidelberg.
Eur J Immunol. 1987 Dec;17(12):1863-6. doi: 10.1002/eji.1830171231.
A role of CD4+ T helper cells in induction of tumor transplant rejection leading to complete regression of a highly metastatic DBA/2 mouse lymphoma was analyzed. Using an anti-CD4 monoclonal antibody (GK1.5) which eliminates T helper cells in vivo and in vitro, we found that CD4+ cells are required for tumor resistance in syngeneic DBA/2 mice or allogeneic but major histocompatibility complex-identical B10.D2 mice. In contrast, in allogeneic C57BL/6 mice tumor rejection was independent of CD4+ cells. An analogous requirement for immune CD4+ cells for in vitro induction of CD8+ tumor-specific cytotoxic T cells was found in these respective strains. The requirement for immune CD4+ cells in vitro could be replaced by recombinant interleukin 2. These results demonstrate a role of CD4+ regulatory T cells and T-T cell cooperation in the induction of anti-tumor immunity and tumor rejection, and point to possible therapeutic interventions in the afferent phase of anti-tumor immune responses.
分析了CD4 +辅助性T细胞在诱导肿瘤移植排斥反应中所起的作用,该反应可导致高转移性DBA / 2小鼠淋巴瘤完全消退。使用一种能在体内和体外消除辅助性T细胞的抗CD4单克隆抗体(GK1.5),我们发现,在同基因DBA / 2小鼠或异基因但主要组织相容性复合体相同的B10.D2小鼠中,CD4 +细胞是肿瘤抗性所必需的。相比之下,在异基因C57BL / 6小鼠中,肿瘤排斥反应与CD4 +细胞无关。在这些相应的品系中,发现体外诱导CD8 +肿瘤特异性细胞毒性T细胞对免疫CD4 +细胞有类似需求。体外对免疫CD4 +细胞的需求可用重组白细胞介素2替代。这些结果证明了CD4 +调节性T细胞和T - T细胞合作在诱导抗肿瘤免疫和肿瘤排斥反应中的作用,并指出了在抗肿瘤免疫反应传入阶段可能的治疗干预措施。